胰高血糖素样肽-1受体激动剂与2型糖尿病患者严重肝脏事件的关联:一项斯堪的纳维亚队列研究
该队列研究基于瑞典、丹麦和挪威2007-2020年全国登记数据,纳入91,479名GLP-1受体激动剂起始者和244,004名二肽基肽酶-4抑制剂起始者,均无除NAFLD/NASH外的慢性肝病史。结果显示,GLP-1受体激动剂使用与严重肝脏事件风险显著降低相关(调整HR 0.85,95%CI 0.75-0.97),主要由代偿性和失代偿性肝硬化减少驱动,而肝细胞癌风险无显著差异。
要点
- GLP-1受体激动剂使用与严重肝脏事件风险降低相关(调整HR 0.85,95%CI 0.75-0.97)。
- 肝硬化(代偿性和失代偿性)风险降低(调整HR 0.85,95%CI 0.75-0.97)。
- 肝细胞癌风险无显著差异(调整HR 1.05,95%CI 0.80-1.39)。
核心结论
- GLP-1受体激动剂的使用与严重肝脏事件风险显著降低相关,该效应由代偿性和失代偿性肝硬化减少驱动。
研究设计与样本
- 基于瑞典、丹麦和挪威2007-2020年全国登记数据的队列研究,纳入91,479名GLP-1受体激动剂起始者和244,004名二肽基肽酶-4抑制剂起始者,均无除NAFLD/NASH外的慢性肝病史。
- 采用倾向评分加权控制混杂,Cox回归估计风险比。
主要发现
- GLP-1受体激动剂组发生608例严重肝脏事件(调整发病率16.9例/10,000人年),二肽基肽酶-4抑制剂组发生1770例(19.2例/10,000人年)。
- 调整HR为0.85(95%CI 0.75-0.97),率差为-2.1(-4.4至0.1)例/10,000人年。
- 代偿性和失代偿性肝硬化的调整HR为0.85(95%CI 0.75-0.97),肝细胞癌的调整HR为1.05(95%CI 0.80-1.39)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Clinical trials suggest that glucagon-like peptide-1 (GLP-1) receptor agonists may have beneficial effects on NAFLD, but the impact on hard hepatic end points is unknown. We assessed the association between the use of GLP-1 receptor agonists and the risk of serious liver events in routine clinical practice. APPROACH AND RESULTS: Cohort study using data from nationwide registers in Sweden, Denmark, and Norway, 2007-2020, including 91,479 initiators of GLP-1 receptor agonists and 244,004 initiators of the active comparator, dipeptidyl peptidase-4 inhibitors, without a history of chronic liver disease other than NAFLD/NASH. The primary outcome was serious liver events: a composite of incident compensated and decompensated cirrhosis and HCC. Secondary outcomes were the individual components of the primary outcome. Cox regression was used to estimate HRs, using propensity score weighting to control for confounding. Users of GLP-1 receptor agonists had 608 serious liver events (adjusted incidence rate: 16.9 events per 10,000 person-years), compared with 1770 events among users of dipeptidyl peptidase-4 inhibitors (19.2 events per 10,000 person-years). The adjusted HR was 0.85 (95% CI: 0.75 to 0.97), and the rate difference was -2.1 (-4.4 to 0.1) events per 10,000 person-years. In secondary outcome analyses, the adjusted HR was 0.85 (0.75 to 0.97) for compensated and decompensated cirrhosis and 1.05 (0.80 to 1.39) for HCC. CONCLUSIONS: The use of GLP-1 receptor agonists was associated with a significantly reduced risk of serious liver events, driven by a reduction of compensated and decompensated cirrhosis.
引用
- Engström A, Wintzell V, Melbye M, et al. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study. Hepatology. 2023. PMID: 38085855. doi:10.1097/HEP.0000000000000712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。